Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Andrew BlauveltEmma Guttman-YasskyAmy S PallerEric L SimpsonMichael J CorkJamie WeismanJohn BrowningWeily SoongXian SunZhen ChenMatthew P KosloskiMohamed A KamalDimittri DelevryChien-Chia ChuangJohn T O'MalleyAshish BansalPublished in: American journal of clinical dermatology (2022)
Video abstract: What is the long-term safety and efficacy profile in adolescents with moderate-to-severe atopic dermatitis treated with the approved dupilumab dose regimen? (MP4 40,966 KB).